Litigation Details for Acorda Therapeutics Inc. v. Accord Healthcare Inc. (D. Del. 2014)

Acorda Therapeutics Inc. v. Accord Healthcare Inc. (D. Del. 2014)

Docket		Date Filed	2014-07-15
Court	District Court, D. Delaware	Date Terminated	2016-08-18
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,007,826; 8,354,437; 8,440,703; 8,663,685
Link to Docket	External link to docket

Details for Acorda Therapeutics Inc. v. Accord Healthcare Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-15				External link to document

Litigation summary and analysis for: Acorda Therapeutics Inc. v. Accord Healthcare Inc. (D. Del. 2014)

Last updated: August 13, 2026

Acorda Therapeutics’ 2014 patent case against Accord Healthcare concerned Accord’s Paragraph IV challenge to Ampyra, Acorda’s extended-release dalfampridine product for improving walking ability in adults with multiple sclerosis. The action was filed in the U.S. District Court for the District of Delaware as No. 1:14-cv-00932. The case was part of a broader Ampyra ANDA litigation campaign involving multiple generic manufacturers. Public docket materials do not show a reported merits opinion or a publicly disclosed settlement term establishing an independent invalidity or noninfringement ruling against Accord.

Acorda Therapeutics v. Accord Healthcare: Ampyra Patent Litigation Analysis

What drug and patents were involved in Acorda v. Accord Healthcare?

The dispute involved Ampyra extended-release tablets, whose active ingredient is dalfampridine, also known as 4-aminopyridine or fampridine outside the United States. Ampyra is approved to improve walking in adults with multiple sclerosis.

Acorda’s asserted patent estate centered on extended-release aminopyridine formulations and related treatment claims. The principal patents associated with the Ampyra litigation included:

Patent	General subject matter	Approximate listed expiration	Relevance
U.S. Patent No. 8,007,826	Sustained-release aminopyridine formulations	2025, subject to patent-term adjustments and regulatory extensions	Core formulation patent
U.S. Patent No. 8,663,685	Additional sustained-release aminopyridine claims	2025, subject to applicable adjustments	Formulation and release-profile coverage
U.S. Patent No. 9,101,628	Later Ampyra-related formulation or treatment claims	2025, subject to applicable adjustments	Later Orange Book-listed protection

The exact patent claims placed in issue depended on Accord’s ANDA certifications and Acorda’s complaint. The litigation was directed at generic substitution of dalfampridine extended-release tablets rather than at a biosimilar product.

When was the Acorda v. Accord case filed?

Acorda filed the action in 2014 after Accord notified Acorda of an ANDA filing containing Paragraph IV certifications against Ampyra patents. The action number was 1:14-cv-00932 in the District of Delaware.

Under the Hatch-Waxman framework, Acorda’s patent suit triggered the statutory stay of FDA approval for the challenged ANDA, generally lasting up to 30 months unless terminated earlier by court action or another statutory event. The case was one of several parallel Ampyra patent actions filed against proposed generic manufacturers.

The Delaware cases reflected a coordinated defense of Ampyra’s patent estate. Other defendants in related proceedings included Mylan, Roxane, Actavis and additional ANDA applicants.

What were Accord Healthcare’s Paragraph IV issues?

Accord’s Paragraph IV challenge likely placed the following issues before the court:

1. Whether the asserted claims were invalid for obviousness.
2. Whether Accord’s proposed product infringed the asserted formulation claims.
3. Whether the patents adequately described and enabled the claimed sustained-release dalfampridine product.
4. Whether the ANDA product would induce infringement of any method-of-use claims.
5. Whether Acorda could obtain an injunction preventing FDA approval and commercial launch.

The practical dispute was whether an ANDA product with the same active ingredient and therapeutic objective could be marketed before expiration of Acorda’s Ampyra patents.

What was the technical basis of Acorda’s Ampyra patent estate?

Acorda’s protection did not depend solely on the chemical identity of dalfampridine. The commercial value was concentrated in the controlled-release formulation.

Sustained-release formulation protection

The Ampyra formulation was designed to release dalfampridine over time. That delivery profile is important because immediate-release aminopyridine exposure can produce a narrower safety margin and less suitable dosing characteristics.

The relevant claim concepts included:

• A dalfampridine-containing oral dosage form.
• Controlled or sustained release of the active ingredient.
• Defined release characteristics over a specified period.
• A dosage strength and administration schedule associated with improved walking ability.
• Formulation features intended to limit rapid systemic exposure.

The formulation patents therefore created a barrier distinct from a basic compound patent. Generic applicants could potentially avoid infringement by using a materially different release mechanism, but they still had to satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.

Method-of-use protection

Acorda also pursued protection for using dalfampridine to improve walking in patients with multiple sclerosis. Method claims can provide commercial value after formulation patents expire, but their enforcement against an ANDA applicant depends on the proposed labeling and the legal theory of induced infringement.

For Ampyra, the label’s express indication created a direct connection between the ANDA product and the claimed therapeutic use. That increased litigation exposure for a generic applicant, although it did not eliminate potential noninfringement arguments based on claim construction, label wording or divided-infringement theories.

What was the central validity risk for Acorda?

The principal validity risk was obviousness. The Federal Circuit’s later Ampyra decision involving Roxane is highly relevant because it addressed the same general patent estate and similar technical arguments.

In Acorda Therapeutics Inc. v. Roxane Laboratories Inc., the Federal Circuit affirmed findings that certain Ampyra patent claims were obvious. The court evaluated prior-art disclosures concerning aminopyridine treatment, sustained-release technology, dosing and the motivation to combine known technical elements. The decision materially weakened the enforceability position of the corresponding Ampyra patents against other ANDA defendants. [2]

The Roxane decision did not automatically dispose of the Accord case. Patent cases remain defendant-specific, and the precise ANDA formulation, claim construction record, defenses and procedural posture can differ. It did, however, reduce Acorda’s leverage in parallel litigation and settlement negotiations.

What was the outcome of Acorda v. Accord Healthcare?

The public record does not identify a published trial judgment resolving the merits of the Accord action. The case appears to have ended without a reported decision establishing that Accord’s product infringed valid, enforceable patent claims.

The most commercially relevant interpretation is that the action was resolved through a negotiated disposition or otherwise terminated before a public merits judgment. The publicly available record does not establish the complete economic terms, launch date, licensing consideration or other settlement provisions.

A docket termination without a merits opinion should not be treated as a finding that Acorda’s patents were valid or that Accord’s product was noninfringing. It indicates only that the dispute did not produce a publicly reported adjudication in that docket.

How did the Accord case compare with Acorda’s Roxane litigation?

Issue	Acorda v. Accord	Acorda v. Roxane
Court	District of Delaware	District of Delaware
Product	Proposed dalfampridine ER tablet	Proposed dalfampridine ER tablet
Legal pathway	Hatch-Waxman Paragraph IV litigation	Hatch-Waxman Paragraph IV litigation
Public merits opinion	No reported merits decision identified	District court and Federal Circuit decisions reported
Key issue	Patent infringement and validity	Obviousness and related patent validity issues
Strategic effect	Resolved without a public merits judgment	Federal Circuit decision weakened Ampyra patent enforcement position
Commercial consequence	Dependent on private disposition and FDA timing	Contributed to generic-entry risk for Ampyra

The Roxane appellate ruling was more consequential for the industry than the Accord docket because it created binding Federal Circuit guidance on the validity of relevant Ampyra claims. Acorda’s ability to maintain exclusivity against remaining defendants was reduced after that ruling.

What was the FDA and Orange Book status of Ampyra?

Ampyra was approved by the FDA as a small-molecule prescription drug, not as a biologic. Generic applicants therefore used the ANDA pathway rather than the biosimilar pathway.

Acorda’s Orange Book strategy relied on listing patents directed to the approved product and its use. The listed patents were relevant to FDA approval timing because a Paragraph IV certification could prompt patent litigation and the statutory approval stay.

The key regulatory points were:

• FDA approval pathway: ANDA for generic dalfampridine extended-release tablets.
• Reference product: Ampyra extended-release tablets.
• Active ingredient: dalfampridine.
• Therapeutic area: multiple sclerosis, with an indication to improve walking.
• Regulatory risk: a generic applicant could face approval delay from the Hatch-Waxman stay.
• Biosimilar exposure: not applicable because dalfampridine is a conventional small molecule.

FDA approval timing and commercial launch would depend on the status of each listed patent, any settlement restrictions, regulatory exclusivity, and the applicant’s ability to satisfy bioequivalence requirements.

What generic-entry risks existed for Ampyra?

The generic-entry risk was substantial because Ampyra’s protection was concentrated in a limited number of formulation patents rather than in a long-lived composition-of-matter patent.

Early launch risk

An early launch could occur if:

• Accord prevailed on invalidity or noninfringement.
• A court denied or lifted injunctive relief.
• A settlement permitted launch before all listed patent expirations.
• A later patent was not enforceable against the specific ANDA product.
• The FDA approved the ANDA after resolution of the statutory stay.

At-risk launch exposure

A generic company could also launch at risk after FDA approval but before final resolution of patent disputes. That strategy would expose the company to damages, an injunction and possible treble damages if willful infringement were established. The strength of that strategy would depend heavily on the Federal Circuit’s treatment of the Ampyra patents and the specific design of the generic formulation.

Formulation-design-around risk

A formulation patent creates a design-around pathway. A generic company might attempt to use a different matrix, coating, release mechanism or excipient combination while preserving bioequivalence. The more narrowly the asserted claims were tied to release characteristics or formulation architecture, the greater the design-around opportunity.

How strong was Acorda’s Ampyra patent estate?

The estate was commercially meaningful but legally vulnerable.

Strengths

• It covered the formulation that supported the approved extended-release product.
• The FDA-approved label linked the product to a defined multiple-sclerosis walking indication.
• Paragraph IV litigation delayed or complicated generic approval.
• The patents extended beyond the initial Ampyra launch period.

Weaknesses

• The estate did not have the durability of a broad, unexpired compound patent.
• Sustained-release technologies were vulnerable to prior-art combinations.
• Parallel litigation increased the risk of inconsistent claim construction and repeated validity challenges.
• The Federal Circuit’s Roxane decision impaired the enforceability position for relevant claims.
• A successful generic formulation design-around could reduce the practical value of formulation claims.

The estate was therefore strongest as a litigation and delay mechanism before the Federal Circuit’s adverse validity ruling. Its long-term exclusionary value was materially lower after that ruling.

Did the case involve a licensing deal or settlement agreement?

No publicly reported settlement terms for Acorda v. Accord Healthcare establish the amount of any payment, the permitted generic launch date, manufacturing restrictions, authorized-generic provisions or license scope.

Confidential Hatch-Waxman settlements are common. Their commercial effect may be reflected in later FDA approval or launch activity, but those events do not disclose all contractual terms. The Accord docket should therefore be treated as a terminated patent dispute rather than as evidence of a public license with defined conditions.

What litigation status matters for investors and competitors?

The principal litigation conclusion is that the Accord case itself did not produce a public merits ruling that preserved the Ampyra patents against Accord. The broader Ampyra litigation record is more important because the Federal Circuit’s decision in the Roxane case established significant invalidity precedent against related claims.

For commercial diligence, the relevant risk hierarchy is:

1. Whether the specific generic applicant obtained FDA approval.
2. Whether a settlement restricted launch timing.
3. Whether the generic product used a formulation within the asserted claims.
4. Whether later-listed patents remained enforceable.
5. Whether the Federal Circuit’s obviousness ruling controlled or strongly influenced the remaining disputes.

Key Takeaways

• Acorda sued Accord Healthcare in the District of Delaware under No. 1:14-cv-00932 over an ANDA for generic Ampyra.
• The dispute concerned dalfampridine extended-release tablets, not a biologic or biosimilar product.
• The relevant Ampyra patent estate included U.S. Patent Nos. 8,007,826, 8,663,685 and later related patents.
• The core patent value was in sustained-release formulation and associated treatment claims.
• No reported public merits judgment against Accord establishes infringement of valid, enforceable claims.
• The Federal Circuit’s later Roxane decision found relevant Ampyra claims obvious, materially weakening Acorda’s broader enforcement position.
• Generic-entry risk increased as formulation patents approached expiration and as the validity record deteriorated.
• Public sources do not disclose complete Accord settlement terms or a definitive Accord-specific launch license.

FAQs About Acorda v. Accord Healthcare

Was Accord Healthcare found to infringe Acorda’s Ampyra patents?

No reported public merits decision in the Accord docket establishes that Accord infringed valid and enforceable Acorda patents.

Did Acorda win the Ampyra patent litigation?

Acorda obtained no publicly reported merits victory against Accord. The broader litigation record included an adverse Federal Circuit decision involving Roxane on the validity of related Ampyra claims.

Is dalfampridine subject to biosimilar competition?

No. Dalfampridine is a small-molecule drug, so competing products use the ANDA generic-drug pathway rather than the biosimilar pathway.

What was the most important Ampyra patent?

U.S. Patent No. 8,007,826 was one of the principal formulation patents associated with Ampyra litigation. Its importance arose from coverage of sustained-release aminopyridine formulations.

What does the case mean for generic Ampyra manufacturers?

The case illustrates the value and limits of formulation patents in Hatch-Waxman litigation. Generic manufacturers faced approval delays and infringement risk, but the Federal Circuit’s later obviousness ruling reduced the strength of Acorda’s exclusionary position.

References

1. U.S. District Court for the District of Delaware. (2014). Acorda Therapeutics Inc. v. Accord Healthcare Inc., No. 1:14-cv-00932. PACER docket records.

2. U.S. Court of Appeals for the Federal Circuit. (2018). Acorda Therapeutics Inc. v. Roxane Laboratories Inc., 903 F.3d 1310.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Patent and Trademark Office. (2008). U.S. Patent No. 8,007,826, Sustained release formulations of aminopyridines.

5. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,663,685.